Trial Profile
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam Given Via the Subcutaneous Route in Primary Antibody Deficient Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Bio Products Laboratory
- 30 Sep 2014 New trial record